HUP0000343A3 - Use for 1,3-propanediol derivatives to prevent rejection after organ transplantation - Google Patents

Use for 1,3-propanediol derivatives to prevent rejection after organ transplantation

Info

Publication number
HUP0000343A3
HUP0000343A3 HU0000343A HUP0000343A HUP0000343A3 HU P0000343 A3 HUP0000343 A3 HU P0000343A3 HU 0000343 A HU0000343 A HU 0000343A HU P0000343 A HUP0000343 A HU P0000343A HU P0000343 A3 HUP0000343 A3 HU P0000343A3
Authority
HU
Hungary
Prior art keywords
organ transplantation
prevent rejection
propanediol derivatives
propanediol
derivatives
Prior art date
Application number
HU0000343A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUP0000343A2 publication Critical patent/HUP0000343A2/hu
Publication of HUP0000343A3 publication Critical patent/HUP0000343A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Light Receiving Elements (AREA)
  • Peptides Or Proteins (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0000343A 1996-11-19 1997-11-17 Use for 1,3-propanediol derivatives to prevent rejection after organ transplantation HUP0000343A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9624038.7A GB9624038D0 (en) 1996-11-19 1996-11-19 Organic compounds

Publications (2)

Publication Number Publication Date
HUP0000343A2 HUP0000343A2 (hu) 2000-12-28
HUP0000343A3 true HUP0000343A3 (en) 2001-06-28

Family

ID=10803173

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000343A HUP0000343A3 (en) 1996-11-19 1997-11-17 Use for 1,3-propanediol derivatives to prevent rejection after organ transplantation

Country Status (24)

Country Link
US (3) US6274629B1 (https=)
EP (2) EP0941082B1 (https=)
JP (2) JP4004070B2 (https=)
CN (2) CN1293876C (https=)
AT (2) ATE369846T1 (https=)
AU (1) AU728420B2 (https=)
BR (1) BR9713105A (https=)
CA (1) CA2270952C (https=)
CZ (1) CZ174999A3 (https=)
DE (2) DE69738033T2 (https=)
DK (1) DK1312359T3 (https=)
ES (2) ES2227726T3 (https=)
GB (1) GB9624038D0 (https=)
HU (1) HUP0000343A3 (https=)
ID (1) ID21568A (https=)
IL (1) IL129824A (https=)
NO (1) NO992259L (https=)
NZ (1) NZ335629A (https=)
PL (1) PL190348B1 (https=)
PT (2) PT1312359E (https=)
RU (1) RU2217136C2 (https=)
SI (1) SI1312359T1 (https=)
SK (1) SK284806B6 (https=)
WO (1) WO1998022100A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1457478B1 (en) 1998-11-11 2017-07-19 Novartis AG Production of 2-amino-2-[2-(4-alkyl-phenyl)ethyl]propane-1,3-diols
CN1411373A (zh) * 1999-12-16 2003-04-16 特瓦制药工业有限公司 制备来氟米特的新方法和新晶形的来氟米特
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
ES2267993T3 (es) * 2001-02-22 2007-03-16 Novartis Ag Uso de agentes de migracion acelerada de linfocitos para la fabricacion de un medicamento para el tratamiento de la funcion retardada del injerto.
CN1507451A (zh) * 2001-04-20 2004-06-23 �±Ȱ·�ķ�ɷ����޹�˾ 可用作前体药物的修饰环孢菌素及其应用
ES2322442T3 (es) * 2001-06-08 2009-06-22 Novartis Ag Tratamiento o profilaxis del rechazo de injertos de celulas productoras de insulina.
GB0117921D0 (en) * 2001-07-23 2001-09-12 Novartis Ag Organic compounds
US7780993B2 (en) * 2001-09-07 2010-08-24 Yeda Research And Development Co. Ltd. Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts
US20040136972A1 (en) * 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
GB0125443D0 (en) 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
BR0306811A (pt) 2002-01-11 2004-10-26 Sankyo Co Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
GB0217777D0 (en) * 2002-07-31 2002-09-11 Novartis Ag Organic compounds
IL165425A0 (en) * 2004-11-28 2006-01-15 Yeda Res & Dev Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
CA2521325C (en) 2003-04-08 2010-09-14 Novartis Ag Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
EP1484057A1 (en) * 2003-06-06 2004-12-08 Aventis Pharma Deutschland GmbH Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
US7524887B2 (en) 2003-06-06 2009-04-28 Sanofi-Aventis Deutschland Gmbh 2-amino-1,3-propanediol compounds for the treatment of acute pain
EP1643983B1 (en) * 2003-06-24 2010-05-05 The University of Connecticut Methods of inhibiting vascular permeability and apoptosis
US7074659B2 (en) * 2003-11-13 2006-07-11 Volterra Semiconductor Corporation Method of fabricating a lateral double-diffused MOSFET (LDMOS) transistor
JP2005272453A (ja) 2004-02-24 2005-10-06 Sankyo Co Ltd アミノアルコール化合物
MX2007001236A (es) * 2004-07-30 2007-03-23 Novartis Ag Formulaciones de compuestos de 2-amino-1, 3-propanodiol.
KR101346527B1 (ko) * 2005-12-15 2013-12-31 미쓰비시 타나베 파마 코퍼레이션 아민 화합물 및 그 의약 용도
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
US9815772B2 (en) * 2013-03-05 2017-11-14 Biocon Limited Process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof
US20180250235A1 (en) 2015-09-18 2018-09-06 Sanovel Ilac Sanayi Ve Ticaret A.S. Fingolimod capsule composition
JP2024521882A (ja) * 2021-05-31 2024-06-04 上海雲晟研新生物科技有限公司 フィンゴリモド薬用塩、製造方法、それを含む医薬組成物及び使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904679A (en) * 1972-05-23 1975-09-09 Upjohn Co 15-Methyl and 15-ethyl prostaglandin F{HD 2{331 {0 {B analogs
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
CA2114015C (en) * 1991-07-25 2002-12-10 Roland A. Newman Recombinant antibodies for human therapy
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5604229A (en) * 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
ES2230571T3 (es) 1995-12-28 2005-05-01 Mitsubishi Pharma Corporation `composicion farmaceutica destinada para la administracion topica que comprende el 2-amino-2-(2-(4-octilfenil)etil) propan-1,3-diol para el tratamiento de las enfermedades causadas por una alteracion inmunitaria.
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
DE69840169D1 (de) * 1997-02-27 2008-12-11 Novartis Ag Arzneimittel zubereitung enthaltend 2-amino-2-ä2-(4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid

Also Published As

Publication number Publication date
DE69738033T2 (de) 2008-04-30
AU5483198A (en) 1998-06-10
DE69738033D1 (de) 2007-09-27
DE69730727D1 (de) 2004-10-21
US20010056124A1 (en) 2001-12-27
PL333463A1 (en) 1999-12-20
EP0941082A2 (en) 1999-09-15
SK65999A3 (en) 1999-12-10
EP1312359B1 (en) 2007-08-15
EP1312359A3 (en) 2004-01-02
CN1237906A (zh) 1999-12-08
EP1312359A2 (en) 2003-05-21
DE69730727T2 (de) 2005-09-22
CN1146411C (zh) 2004-04-21
JP4004070B2 (ja) 2007-11-07
ES2227726T3 (es) 2005-04-01
ID21568A (id) 1999-06-24
ATE369846T1 (de) 2007-09-15
US6274629B1 (en) 2001-08-14
RU2217136C2 (ru) 2003-11-27
PT941082E (pt) 2004-12-31
WO1998022100A3 (en) 1998-06-25
IL129824A0 (en) 2000-02-29
CA2270952C (en) 2007-09-18
IL129824A (en) 2003-07-31
NO992259D0 (no) 1999-05-10
US6486209B2 (en) 2002-11-26
NO992259L (no) 1999-05-10
NZ335629A (en) 2001-09-28
HK1022639A1 (en) 2000-08-18
CA2270952A1 (en) 1998-05-28
PL190348B1 (pl) 2005-11-30
AU728420B2 (en) 2001-01-11
ATE275947T1 (de) 2004-10-15
SI1312359T1 (sl) 2008-08-31
DK1312359T3 (da) 2007-10-08
GB9624038D0 (en) 1997-01-08
JP2001503780A (ja) 2001-03-21
BR9713105A (pt) 2000-04-11
HUP0000343A2 (hu) 2000-12-28
ES2289041T3 (es) 2008-02-01
WO1998022100A2 (en) 1998-05-28
JP2004256554A (ja) 2004-09-16
CN1515253A (zh) 2004-07-28
EP0941082B1 (en) 2004-09-15
PT1312359E (pt) 2007-11-09
CZ174999A3 (cs) 1999-08-11
CN1293876C (zh) 2007-01-10
US20030069315A1 (en) 2003-04-10
SK284806B6 (sk) 2005-11-03

Similar Documents

Publication Publication Date Title
HUP0000343A3 (en) Use for 1,3-propanediol derivatives to prevent rejection after organ transplantation
DE69730039D1 (de) Herztransplantate
AU5219198A (en) Method to prevent transplant rejection
PL331602A1 (en) Pyrido- or pyrimido-substituted 6,6- or 6,7-bicyclic derivatives
DE69635951D1 (de) Doppelt unterstütztes intraluminales transplantat
GB2319250B (en) Derivatives of 6,8-Difluoro-7-Hydroxycoumarin
IL130058A0 (en) 8-Azabicyclo(3.2.1)octane-8-azabicyclo(3.2.1)oct-6-ene-9-azabicyclo(3.3.1)nonane-9-aza-3-oxabicyclo (3.3.1)nonane- and 9-aza-3-thiabicyclo(3.3.1)nonane derivatives their preparation and their use as insecticides
HUP9903965A3 (en) Substituted 6,5-hetero-bicyclic derivatives
ZA977652B (en) Substituted 6,6-hetero-bicyclic derivatives
AU1455095A (en) 1,2,4-oxadiazole derivatives and their use as parasiticides for animals
PL329121A1 (en) Substituted derivatives of 1,2,3,4-tetrahydronaphtalene
DK1021444T3 (da) 5H-Pyrrolo-[2,1-c][1,4]benzodiazepin-3-carboxamidderivat
AUPN880396A0 (en) Animal model for transplantation
HUP9903388A3 (en) Fungicidal composition
EP0694538A3 (en) 2-Benzyloxy-4-phenoxy pyrimidine derivatives, process for their preparation and herbicidal compositions containing them
GB2292057B (en) Angler's aid
HU9601936D0 (en) 3-aryl alkenyl-1,2,4-oxadiazole derivatives and their use as parasiticides for animals
AU6623796A (en) Improvements in or relating to fishing
HU9701463D0 (en) Arrangements for harvesting legomes
IL129715A0 (en) Substituted benzo (1,4) dioxanes as antiobesity agents
IL147099A0 (en) New use for 1,3-propanediol derivatives
PL316109A1 (en) Skin transplantation instrument
GB9619534D0 (en) Fungicidal composition
GB9713945D0 (en) Improvements relating to tissue transplantation
SI0920429T1 (en) Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees